Back to news

Natera slides as recent rally cools despite fresh product and analyst momentum

Investivoq PriceTracker

Natera (NTRA) is down 3.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears to be more of a pullback after a sharp recent run than a reaction to a clear new negative development. Natera entered the session after a strong prior-day gain and a string of favorable updates, so some investors may be locking in profits while the stock trades near elevated levels.

Details:

  • The stock had climbed to about $404.79 on October 15 after gaining roughly 2.5%, then slipped back the next day, which fits a near-term profit-taking pattern.
  • Natera disclosed on October 15 that its Signatera MRD test was named to a major innovation list for 2026, adding to an already strong flow of positive company news rather than introducing a new setback.
  • Earlier in the week, the company also announced a colorectal cancer trial collaboration and highlighted recent oncology-related study activity, reinforcing a constructive business backdrop.
  • Wall Street sentiment has remained supportive, with multiple firms recently lifting price targets, so today’s weakness looks more like digestion of prior gains than a fundamental reset. This could be because traders were trimming positions after a fast move higher.

    • Sources:

    Natera Investor Relations, Benzinga, ChartExchange

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $NTRA Insider Trading Activity

    NTRA Insider Trades

    $NTRA insiders have traded $NTRA stock on the open market 265 times in the past 6 months. Of those trades, 0 have been purchases and 265 have been sales.

    Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:

    • MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 65 sales selling 265,157 shares for an estimated $75,850,279.
    • JONATHAN SHEENA has made 0 purchases and 80 sales selling 62,053 shares for an estimated $19,441,407.
    • ROELOF BOTHA has made 0 purchases and 6 sales selling 78,000 shares for an estimated $17,184,092.
    • DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 22 sales selling 54,812 shares for an estimated $14,052,243.
    • STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 28 sales selling 59,681 shares for an estimated $13,838,169.
    • SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 33 sales selling 40,023 shares for an estimated $11,583,173.
    • HERM ROSENMAN sold 16,530 shares for an estimated $4,132,500
    • JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 8 sales selling 11,942 shares for an estimated $3,310,904.
    • MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 16 sales selling 11,717 shares for an estimated $2,666,293.
    • GAIL BOXER MARCUS has made 0 purchases and 4 sales selling 11,000 shares for an estimated $2,389,328.
    • ROWAN E CHAPMAN has made 0 purchases and 2 sales selling 3,099 shares for an estimated $679,636.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive NTRA Data Alerts
    Get market-moving data, filings, and signals for NTRA in real time.
    Sign Up

    $NTRA Hedge Fund Activity

    We have seen 493 institutional investors add shares of $NTRA stock to their portfolio, and 309 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • JPMORGAN CHASE & CO added 12,865,346 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,492,298,171
    • PRICE T ROWE ASSOCIATES INC /MD/ removed 3,162,981 shares (-26.0%) from their portfolio in Q2 2026, for an estimated $858,591,192
    • FMR LLC added 2,897,142 shares (+113.4%) to their portfolio in Q2 2026, for an estimated $786,429,195
    • GOLDMAN SACHS GROUP INC added 952,921 shares (+124.2%) to their portfolio in Q2 2026, for an estimated $258,670,405
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 806,536 shares (+inf%) to their portfolio in Q2 2026, for an estimated $218,934,197
    • T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 795,962 shares (+242.8%) to their portfolio in Q2 2026, for an estimated $216,063,884
    • WELLINGTON MANAGEMENT GROUP LLP removed 727,855 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $197,576,239

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $NTRA Government Contracts

    We have seen $791,200 of award payments to $NTRA over the last year.

    Here are some of the awards which we have have seen pay out the most over the last year:

    • DNA TESTING: $230,000
    • TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $80,400

    To track government contracts to publicy traded companies, check out Investivoq's government contracts dashboard. You can access data on government contracts through the Investivoq API government contracts endpoint.

    $NTRA Analyst Ratings

    Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • BTIG issued a "Buy" rating on 06/23/2026

    To track analyst ratings and price targets for $NTRA, check out Investivoq's $NTRA forecast page.

    $NTRA Price Targets

    Multiple analysts have issued price targets for $NTRA recently. We have seen 11 analysts offer price targets for $NTRA in the last 6 months, with a median target of $275.0.

    Here are some recent targets:

    • Tejas Savant from Morgan Stanley set a target price of $310.0 on 07/09/2026
    • Daniel Markowitz from Evercore ISI Group set a target price of $300.0 on 07/06/2026
    • Subbu Nambi from Guggenheim set a target price of $290.0 on 06/29/2026
    • Eve Burstein from Bernstein set a target price of $310.0 on 06/26/2026
    • Luke Sergott from Barclays set a target price of $260.0 on 06/24/2026
    • Mark Massaro from BTIG set a target price of $275.0 on 06/24/2026
    • Dan Leonard from RBC Capital set a target price of $275.0 on 06/11/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.